Advertisement

Loading...

Mabpharm Limited

2181.HKHKSE
Healthcare
Biotechnology
HK$0.53
HK$0.03(6.000%)
Hong Kong Market is Open • 10:07

Mabpharm Limited (2181.HK) Stock Competitors & Peer Comparison

See (2181.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2181.HKHK$0.52-1.89%2.1B50.00HK$0.01N/A
6160.HKHK$185.80+8.59%257.8B115.17HK$1.49N/A
1801.HKHK$91.45+6.21%146.1B160.19HK$0.53N/A
2269.HKHK$35.24+12.37%136.5B25.21HK$1.31N/A
9926.HKHK$139.70+4.96%119.8B-119.45-HK$1.09N/A
1177.HKHK$6.38+9.06%105.3B39.27HK$0.15+1.53%
1530.HKHK$25.66+5.68%53.4B20.77HK$1.09+1.10%
9995.HKHK$109.90+11.18%52.7B65.62HK$1.46N/A
3759.HKHK$20.82+13.96%51.4B19.40HK$0.97+1.16%
2696.HKHK$75.20+7.97%37.9B40.79HK$1.71N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2181.HK vs 6160.HK Comparison April 2026

2181.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2181.HK stands at 2.1B. In comparison, 6160.HK has a market cap of 257.8B. Regarding current trading prices, 2181.HK is priced at HK$0.52, while 6160.HK trades at HK$185.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2181.HK currently has a P/E ratio of 50.00, whereas 6160.HK's P/E ratio is 115.17. In terms of profitability, 2181.HK's ROE is +0.44%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 2181.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2181.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions